CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleLevered free cash flow is $19.65M, above the global median of $16.24M
- PositionGross margin is 85.1%, higher than 95% of its Medical Devices peers (median 61%)
- Interpretations8 currently firing — 8
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
442.22MUSDvs all stocks (USD)
Revenue (TTM)
90.44MUSDvs all stocks (USD)
Profit Margin
0.62%vs Medical Devices peers
Beta
0.4910xvs all stocks
52-Week Change
13.16%vs all stocks
Market Capitalization
442.22MUSDvs all stocks (USD)
Enterprise Value
366.60MUSDvs all stocks (USD)
Forward P/E
-25.20xvs Medical Devices peers
PEG Ratio
-6.43xvs Medical Devices peers
Price to Sales (TTM)
4.90xvs Medical Devices peers
Price to Book (MRQ)
3.93xvs Medical Devices peers
Enterprise to Revenue
4.05xvs Medical Devices peers
Gross Margin
85.05%vs Medical Devices peers
Profit Margin
0.62%vs Medical Devices peers
Operating Margin
-6.55%vs Medical Devices peers
Return on Assets (TTM)
-0.95%vs Medical Devices peers
Return on Equity (TTM)
0.58%vs Medical Devices peers
Revenue (TTM)
90.44MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.50USDUpdated Jul 18, 2026Quarterly Revenue Growth
26.30%vs Medical Devices peers
Gross Profit (TTM)
77.75MUSDvs all stocks (USD)
EBITDA (TTM)
1.01MUSDvs all stocks (USD)
Net Income (TTM)
561.00KUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
26.33%vs Medical Devices peers
Operating Cash Flow (TTM)
21.17MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
19.65MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
85.23MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
11.80MUSDFY2025 · Dec 31, 2025Gross Profit
73.43MUSDFY2025 · Dec 31, 2025Operating Income
660.00KUSDvs all stocks (USD)
Pre-tax Income
3.51MUSDFY2025 · Dec 31, 2025Income Tax Expense
810.00KUSDFY2025 · Dec 31, 2025Net Income
2.70MUSDFY2025 · Dec 31, 2025EBIT
660.00KUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.01MUSDFY2025 · Dec 31, 2025Research & Development
29.25MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
43.53MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.0800USDFY2025 · Dec 31, 2025EPS (Diluted)
0.0700USDFY2025 · Dec 31, 2025Basic Shares Outstanding
35.82MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
35.82MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
2.70MUSDFY2025 · Dec 31, 2025Operating Cash Flow
27.63MUSDFY2025 · Dec 31, 2025Free Cash Flow
26.09MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
43.45MUSDFY2025 · Dec 31, 2025Income Tax Paid
1.54MUSDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
2.70MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
349.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
24.23MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-854.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
4.77MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.56MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.55MUSDFY2025 · Dec 31, 2025Purchase of Investments
-93.22MUSDFY2025 · Dec 31, 2025Sale of Investments
68.17MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-26.59MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Common Stock Repurchase
-6.00MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-5.52MUSDFY2025 · Dec 31, 2025Shares Outstanding
34.47MSharesUpdated Jul 18, 2026Float Shares
28.60MSharesUpdated Jul 18, 2026Shares Short
2.87MSharesUpdated Jul 18, 2026Short Ratio
4.67daysvs all stocks
Short % of Shares Outstanding
9.05%vs all stocks
% Held by Insiders
8.13%vs all stocks
% Held by Institutions
49.02%vs all stocks
Total Cash (MRQ)
89.30MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.59USDUpdated Jul 18, 2026Total Debt (MRQ)
907.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0080xvs Medical Devices peers
Current Ratio (MRQ)
11.24xvs Medical Devices peers
Book Value per Share (MRQ)
3.27USDUpdated Jul 18, 2026Total Assets
123.63MUSDvs all stocks (USD)
Total Current Assets
119.53MUSDFY2025 · Dec 31, 2025Total Liabilities
12.41MUSDFY2025 · Dec 31, 2025Total Non-current Assets
4.10MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.46MUSDFY2025 · Dec 31, 2025Total Current Liabilities
10.95MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
43.45MUSDFY2025 · Dec 31, 2025Other Short-term Investments
47.58MUSDFY2025 · Dec 31, 2025Accounts Receivable
11.74MUSDFY2025 · Dec 31, 2025Inventory
10.25MUSDFY2025 · Dec 31, 2025Accounts Payable
2.66MUSDFY2025 · Dec 31, 2025Short-term Debt
101.00KUSDFY2025 · Dec 31, 2025Long-term Debt
835.00KUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
628.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
347.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-528.85MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
111.22MUSDvs all stocks (USD)
52-Week Low
8.12USDUpdated Jul 18, 202652-Week High
13.74USDUpdated Jul 18, 202652-Week Change
13.16%vs all stocks
Beta
0.4910xvs all stocks
50-Day MA
11.76USDUpdated Jul 18, 2026200-Day MA
10.38USDUpdated Jul 18, 2026Avg 10-Day Volume
320.35KSharesUpdated Jul 18, 2026Avg 30-Day Volume
512.30KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
0.0100USDUpdated Jul 18, 2026Other Income / Expense
-70.00KUSDFY2025 · Dec 31, 20258 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
How does this company use capital?
Cash-Backed Growth Configuration
Revenue has grown steadily, and the cash arriving matches reported profit.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
SBC-to-Net-Income Elevated, SBC-to-Revenue Elevated, And Diluted Share Count Growing (6Y CAGR)
Pay in shares is large next to its revenue and its profit, and the share count keeps rising.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 85.1%, higher than 95% of its Medical Devices peers (median 61%)Significant
Gross margin: 0.85Industry median: 0.61Industry P95: 0.85Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.85Profit Margin: 0.01
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Levered free cash flow is $19.65M, above the global median of $16.24MNotable
Levered free cash flow (USD): 19,651,124Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Baotou Dongbao Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Clover Biopharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Rezolute, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangxi Synergy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hubei Goto Biopharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Varex Imaging Corporation
Tier 1ProductionApproval-Gated PipelineRule
Shoulder Innovations, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Benitec Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jw Pharmaceutical Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Haisen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
King Slide Works Co., Ltd.
5 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration
Promotora y Operadora de Infraestructura, S.A.B. de C.V.
5 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration
TWFG, Inc.
5 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration